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ABSTRACT The application of an equilibrium infusion method for measuring spe-
cific in vivo radioligand binding in the conscious rat brain was evaluated for two ligands
of the dopaminergic system, (1)-a-[11C]dihydrotetrabenazine (DTBZ) and d-threo-
[11C]methylphenidate (MePhen). Both radioligands can be successfully utilized to reach
equilibrium distributions in rat brain within 1 h; combinations of tritiated and carbon-
11-labeled radiotracers can furthermore be used to obtain simultaneous measures of the
neuronal membrane dopamine transporter (using [3H]MePhen) and vesicular mono-
amine transporter (using [11C]DTBZ) in the same animal. These studies provided
quantitative measures of distribution volume ratios, which represent specific radioli-
gand binding. Stereospecificity of in vivo binding was demonstrated using equilibrium
infusions of the low-affinity isomers of each ligand, (2)-a-[11C]dihydrotetrabenazine
(DTBZ) and l-threo-[11C]methylphenidate, both of which produced uniform brain distri-
butions and no specific binding. Specific binding of (1)-a-[11C]dihydrotetrabenazine was
blocked by co-infusion of tetrabenazine, but was unaffected by administration of meth-
ylphenidate, haloperidol, or apomorphine. Specific binding of d-threo-[11C]methylpheni-
date, conversely, was blocked with unlabeled methylphenidate but not affected by
tetrabenazine or the dopamine receptor ligands. Equilibrium measures of in vivo radio-
ligand binding, as utilized in this study, offer a quantitative means to evaluate acute and
chronic drug effects on in vivo radioligand binding in the rat brain. Synapse 43:
188–194, 2002. © 2002 Wiley-Liss, Inc.
INTRODUCTION
In recent years there have been significant advances
in our understanding of the structure and functioning
of the transporters for neurotransmitters, particularly
the neuronal membrane and vesicular transporters for
the monoamines (Olivier et al., 2000). Alterations in
the number or functioning of these neurotransmitter
transporters, and the relationships between them, may
be important parts of such diverse human health prob-
lems as neurodegeneration, drug abuse, and psychiat-
ric diseases. With the availability of in vitro methods
utilizing cloned and expressed transporters and animal
models of altered levels of these transporters (Gainet-
dinov et al., 1999), one can expect more advances to be
made in our knowledge of the role of these proteins in
normal and diseased brain function. Even more excit-
ing is the potential of taking this basic biochemical
knowledge to the living human patient, using in vivo
imaging methods such as positron emission tomogra-
phy (PET) (Brooks, 1997; Stoessl and Ruth, 1998) and
single photon emission computed tomography (SPECT)
(Kugaya et al., 2000) measures of transporter numbers
or functions.
Many research groups have investigated in vivo ra-
dioligand methods for studying the neuronal mem-
brane dopamine transporter (DAT) (Carroll et al.,
1995). Less effort has been devoted to the vesicular
monoamine transporter (VMAT2), partly due to the
more limited selection of potential radioligands, but a
successful in vivo radioligand for this transporter is
also now available (Kilbourn, 1994). The availability of
these radioligands provides opportunities to examine
neurochemistry in intact animal models, particularly
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in rodents where neurotoxin, surgical, or genetic mod-
els of numerous neurological diseases are currently
available or actively being developed. In vivo studies of
radioligand binding to DAT or VMAT2 would also per-
mit evaluation of recently described mechanisms for
phosphorylation-dependent regulation of transporter
functions (Pristupa et al., 1998; Reith and Chen, 1997).
Methods for using in vivo radiotracers in rodents vary
widely, including 1) very simple determinations of ra-
dioactivity concentrations at a single time point after
administration, 2) construction of tissue time–activity
curves using groups of animals at distinct time points,
and 3) attempts to define the time-dependent regional
brain pharmacokinetics using small animal imaging
devices. Whereas the last approach would provide in-
formation most like that obtained in humans using
PET or SPECT imaging studies, small animal imaging
devices with the needed resolution and sensitivity
(Hume et al., 1998) are as yet not widely available. Ex
vivo measures of regional brain tissue radioactivity
concentrations at multiple distinct time points, using
groups of animals, combined with pharmacokinetic
analysis of the extrapolated time-dependent distribu-
tions offers an intermediate method for performing
such in vivo animal studies, but that is a time- and
resource-intensive process requiring large numbers of
animals to accurately define the radiotracer pharma-
cokinetics. The simplest technique available is the bo-
lus injection of a radiotracer and determination of re-
gional brain distributions at a single time point
selected to represent a steady state or transient equi-
librium; specific binding is then estimated as the sim-
ple ratio of radioactivity in one region over a second
region selected as representing nonspecific binding.
However, this approach may not be appropriate when
radioligands do not reach an equilibrium distribution
within the experimental time period (Gatley et al.,
2000).
As an alternative to bolus injections, we and others
(Endres and Carson, 1998; Kilbourn and Sherman,
1997) have investigated the application of an infusion
to equilibrium approach to radiotracer administra-
tions; regional brain distributions of radioactivity need
be determined at only one time point after equilibrium
is reached, simplifying the method and minimizing the
requirement for large numbers of animals. At equili-
brium the relative concentrations of radioactivity be-
tween regions of the brain remains constant and the
determination of regional brain concentrations and
blood concentrations of authentic radiotracer allows
simple calculation of the regional distribution volumes
(termed DV or Vd) for the radiotracer. Furthermore,
the use of a region with minimal specific binding allows
calculation of regional distribution volume ratios
(DVR) (Carson, 2000; Logan, 2000) and the regional
binding potentials (BP 5 DVR 2 1). The infusion pro-
tocol in animals thus appears particularly appealing
and can provide essentially the same estimates of spe-
cific binding generated by imaging studies of radiotrac-
ers in the human brain.
We have previously reported the application of the
infusion to equilibrium approach to in vivo quantifica-
tion of (1)-a-[3H]DTBZ binding to the VMAT2 in rat
brain (Kilbourn and Sherman, 1997). Although a large
number of radioligands have been developed for in vivo
studies of the dopamine receptors and the neuronal
membrane transporter for dopamine (DAT), the equiv-
alent equilibrium infusion approach in small animals
has not been applied to those ligands. We report here
the 1) evaluation of infusion to equilibrium methods in
conscious rats for the DAT radioligand d-threo-[3H]-
methylphenidate ([3H]MePhen); 2) comparison of spe-
cific binding estimates from bolus infusion, single time
point studies with the equilibrium-derived binding po-
tentials for [3H]MePhen and (1)-a-[11C]DTBZ; and 3)
development and application of dual equilibrium infu-
sion radiotracer methods for simultaneous measure-
ment of d-threo-[3H]MePhen (DAT) and (1)-a-[11C]-




activity 83 Ci/mmol) was prepared (Amersham, Arling-
ton Heights, IL, USA) by a two-step synthesis involving
[3H]methylation of a suitably protected ritalinic acid
precursor, following the procedure used for synthesis of
d-threo-[11C]methylphenidate (Ding et al., 1994). The
d-threo- and l-threo-isomers of [11C]methylphenidate
(specific activities . 500 Ci/mmol) were prepared by
[11C]methylation of the appropriate ritalinic acid
precursors followed by deprotection. The (1)- and (2)-
isomers of a-[11C]dihydrotetrabenazine (specific activ-
ities . 500 Ci/mmol) were prepared by [11C]methyla-
tion of the corresponding 9-O-desmethyl precursors, by
methods previously described (Jewett et al., 1997).
Tetrabenazine was obtained from ICN Biomedicals
(Aurora, IL, USA) and methylphenidate hydrochloride,
apomorphine, and haloperidol were obtained from Re-
search Biochemicals (Natick, MA, USA). All drugs and
radiotracers were administered as solutions in isotonic
saline.
Radiotracer and drug administration protocols
All studies were done in Sprague-Dawley CD rats
(150–200 g; Charles Rivers, Portage, MI, USA). Under
sodium pentobarbital anesthesia, the animals were
prepared for intravenous radiotracer injections by in-
cision of the skin and insertion of a catheter into one or
both femoral veins. The incisions were then closed and
the animal placed in a plastic restrainer tube and al-
lowed to awaken; all studies were done using animals
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in the fully awake but restrained state. Drugs or saline
(controls) injections were done via the femoral vein
catheter. Radiotracer injections were done through the
femoral vein catheters using a Harvard programmable
infusion pump. Bolus administrations were done using
a 1-min infusion of radiotracer in a volume of 1 mL.
Equilibrium infusion studies were performed using a
bolus administration of 66.6% of the dose (1 mL) over a
1-min period, followed by constant infusion of the re-
maining 33.3% (0.5 mL) of the dose over the remaining
59 min (for 1-h infusion studies) or 119 min (2-h infu-
sion studies).
Groups of 2–4 animals were used at a single exper-
imental session and experiments repeated to achieve
the group sizes shown in Table I. At designated times
after initial bolus or infusion of radiotracers, animals
were killed by i.v. injection of an overdose of sodium
pentobarbital and the brain rapidly removed and dis-
sected according to a slight modification of a literature
method (Glowinski and Iversen, 1966) into samples of
striatum, cortex, hippocampus, hypothalamic region,
thalamus, pons/medulla, and cerebellum. Tissue sam-
ples were then weighed and counted: carbon-11 was
determined immediately using an automated g-
counter. Tissue solubolizer was added and after diges-
tion (2–3 days) scintillation fluid was added and the
sample counted for tritium (automatic b-counter). Data
were calculated as percent injected dose/gram tissue
(%ID/g).
For all studies the specific binding was estimated by
calculating the concentration ratios of regions of inter-
est to cortex as the reference region. For infusion stud-
ies, this measure is termed the distribution volume
ratio (DVR).
Statistics
Comparisons between groups were evaluated either
with a Student t-test or with a repeated measures




The regional brain distribution of radioactivity after
bolus and equilibrium administration of (1)-a-[3H]-
DTBZ has been previously reported (Kilbourn and
Sherman, 1997). In this study, we compared the re-
gional brain distribution of the carbon-11-labeled
tracer at a longer time point after bolus administration
(30 min) with that obtained using infusion to equilib-
rium. Use of the longer time point for sampling after
bolus injection produces an even larger bias in the
estimates of specific binding, as the striatum/cortex
ratio significantly exceeds the value obtained at equi-
librium (Table I) and is higher than obtained at 15 min
(Kilbourn and Sherman, 1997). Using either the 30-
min bolus sampling point or infusion to equilibrium
method; however, highest concentrations of the radio-
ligand can be clearly demonstrated in both the stria-
tum and the hypothalamic region.
(2)-a-[11C]dihydrotetrabenazine ((2)-a-[11C]dtbz)
The bolus 1 infusion administration of (2)-a-
[11C]DTBZ, the inactive isomer (Ki 5 4 micromole:
Kilbourn et al., 1995) produced a nearly uniform brain
distribution of radioactivity, with no evidence for spe-
cific binding in any region (Table I).
d-threo-[3H]methylphenidate
The regional brain distribution of d-threo-[3H]Me-
Phen was determined at 30 min following bolus admin-
istration and after 30 or 60 min of a bolus 1 infusion
protocol (Table II). In a separate experiment, the re-
gional distribution of radioactivity was also determined
using infusion of the carbon-11-labeled radiotracer.
Distribution volume ratios for the infusion studies
were equivalent for all three groups, with specific bind-
ing only detected in the striatum; in contrast to the
results with DTBZ, the bolus administration of d-threo-
[3H]MePhen and sampling at 30 min provided a stria-
tum/cortex ratio more similar to that obtained using
TABLE I. Regional radioactivity concentration ratios for isomers of a-dihydrotetrabenazine (DTBZ) in rat brain
Radioligand Protocol N Drug Striatum
Tissue/cortex
Hypothalamus Hippocampus Thalamus
(1)-[11C]DTBZ bol, 30 min 8 None 4.12 6 0.39 1.93 6 0.12 0.94 6 0.08 0.95 6 0.07
(1)-[3H]DTBZ bol, 15 min 6 None 3.35 6 0.09 2.64 6 0.27 1.28 6 0.03 1.53 6 0.11
(1)-[11C]DTBZ1 inf, 60 min (control) 11 None 2.79 6 0.17 1.52 6 0.22 0.90 6 0.05 0.87 6 0.06
(2)-[11C]DTBZ inf, 60 min 4 None 0.98 6 0.01* 0.87 6 0.10* 0.95 6 0.03 0.92 6 0.08
(1)-[11C]DTBZ1 inf, 60 min 8 MePhen 2.99 6 0.17 1.52 6 0.22 0.90 6 0.05 1.02 6 0.30
(1)-[11C]DTBZ1 inf, 60 min 8 TBZ 0.98 6 0.11* 0.87 6 0.10* 0.95 6 0.03 0.83 6 0.02
(1)-[11C]DTBZ1 inf, 60 min 4 Haloperidol 3.13 6 0.29 1.29 6 0.07 0.93 6 0.04 0.95 6 0.07
(1)-[11C]DTBZ1 inf, 60 min 8 Apomorphine 2.56 6 0.32 1.14 6 0.12 0.92 6 0.10 0.91 6 0.14
Determined following either bolus injection (bol) or administration using a programmed bolus 1 constant infusion (inf) protocol. Methylphenidate (MePhen) and
tetrabenazine (TBZ) were co-infused with radiotracer and haloperidol and apomorphine administered 30 min prior. Tissue/cortex ratios determined following the
infusion protocol represent equilibrium distribution volume ratios (DVR). Data are shown as mean 6 SD.
1Studies performed using dual radiotracer infusions.
*P , 0.005 vs control (1)-[11C]DTBZ infusion study.
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the constant infusion protocol. The regional distribu-
tions of radioactivity were identical after 30 and 60 min
of infusion, supporting that equilibrium distribution of
the radiotracer had been reached by 60 min (or likely
earlier).
l-threo-[3H]methylphenidate
Equilibrium infusion of the low-affinity l-threo-
[11C]MePhen gave a uniform distribution of radioactiv-
ity with no evidence of specific binding in the striatum
(Table II).
Dual radiotracer studies
Regional distribution volume ratios for (1)-a-
[11C]DTBZ and d-threo-[3H]MePhen were next deter-
mined using a dual-radiotracer infusion protocol. In
control studies (n 5 4), tissue concentrations and
distribution volume ratios for both radiotracers were
essentially identical to those obtained in the prior sin-
gle radiotracer studies.
Significant and essentially complete reductions in
striatal and hypothalamic DVR were obtained for (1)-
a-[11C]DTBZ with coadministration of tetrabenazine
(Table I), with tissue distribution volume ratios iden-
tical to those found with the inactive (2)-isomer. Prior
administration of tetrabenazine, however, had no effect
on the equilibrium distribution of d-threo-[3H]MePhen
(Table II). Pretreatment of rats with methylphenidate
produced the opposite results, no effect on equilibrium
(1)-a-[11C]DTBZ distribution (Table I) but a significant
reduction of d-threo-[3H]MePhen binding in the stria-
tum (Table II).
Using the dual radiotracer infusion protocol, no sig-
nificant effects of a dopamine receptor antagonist (hal-
operidol) or agonist (apomorphine) on the equilibrium
distribution of d-threo-[3H]MePhen and (1)-a-[11C]-
DTBZ could be demonstrated.
DISCUSSION
The in vivo infusion to equilibrium method for deter-
mination of regional specific binding in rat brain has
been evaluated for two radioligands currently in clini-
cal use for the study of the dopaminergic system:
d-threo-[11C]methylphenidate (MePhen) and (1)-a-
[11C]dihydrotetrabenazine (DTBZ). In prior bolus stud-
ies in animals and humans, it was apparent that these
ligands show readily reversible binding brain with
pharmacokinetics suitable for an infusion to equilib-
rium study design and such infusion protocols have
been reported in rats and humans for (1)-a-[11C/
3H]DTBZ (Kilbourn and Sherman, 1997; Koeppe et al.,
1997). In this study, we have demonstrated that
d-threo-[11C]MePhen is also a very good radioligand for
this approach to quantification of in vivo regional bind-
ing in rodent brain. As there are reported significant
effects of common anesthetics on in vivo radiotracer
distributions all studies were performed in the awake
rat brain.
Regional brain distributions of radioligands
Following either bolus administration or use of a
bolus 1 infusion protocol, both radioligands produced a
heterogeneous regional brain distribution of radioac-
tivity, with highest concentrations found in the stria-
tum; this is consistent with the known distribution of
the DAT and the VMAT2 and similar to previous bolus
studies using (1)-a-[3H]DTBZ (Kilbourn and Sherman,
1997) and d-threo-[3H]MePhen (Ding et al., 1994; Gat-
ley et al., 1995). For (1)-a-[11C]DTBZ, there is an in-
termediate concentration of radioactivity in the hypo-
thalamic region, reflecting the binding of the
radioligand to the VMAT2 in the serotonergic and ad-
renergic neurons located in that region of the brain.
For d-threo-[3H]MePhen, which is more specific for the
dopaminergic neurons, no significant concentration of
radioligand is noted in any other brain region than the
striatum. With both radioligands, equilibrium infusion
of the low-affinity stereoisomer ((2)-a-[11C]DTBZ),
Ki 5 4 mmol; l-threo-[
11C]MePhen, IC50 5 540 nM
(Gatley et al., 1996)) produced uniform brain distribu-
tions and tissue concentration ratios near unity.
TABLE II. Regional radioactivity concentration ratios for isomers of methylphenidate (MePhen) in rat brain
Radioligand Protocol N Drug Striatum
Tissue/cortex
Hypothalamus Hippocampus Thalamus
d-threo-[3H]MePhen bol, 30 min 8 None 1.76 6 0.17 0.86 6 0.05 0.99 6 0.08 —
d-threo-[3H]MePhen inf, 30 min 8 None 1.61 6 0.06 0.91 6 0.07 1.00 6 0.05 0.77 6 0.06
d-threo-[3H]MePhen1 inf, 60 min (control) 7 None 1.54 6 0.13 0.85 6 0.13 1.01 6 0.16 0.64 6 0.08
d-threo-[11C]MePhen inf, 60 min 4 None 1.54 6 0.06 0.87 6 0.02 0.96 6 0.02 0.73 6 0.03
l-threo-[11C]MePhen inf, 60 min 4 None 1.04 6 0.01* 0.95 6 0.03 1.03 6 0.01 0.87 6 0.01
d-threo-[3H]MePhen1 inf, 60 min 8 MePhen 0.99 6 0.04* 0.87 6 0.08 1.01 6 0.06 0.62 6 0.04
d-threo-[3H]MePhen1 inf, 60 min 8 TBZ 1.53 6 0.14 0.78 6 0.06 0.96 6 0.03 0.75 6 0.05
d-threo-[3H]MePhen1 inf, 60 min 4 Haloperidol 1.65 6 0.13 0.84 6 0.08 1.10 6 0.03 0.83 6 0.03
d-threo-[3H]MePhen1 inf, 60 min 8 Apomorphine 1.61 6 0.13 0.85 6 0.04 1.01 6 0.03 0.71 6 0.03
Determined following either bolus injection (bol) or administration using a programmed bolus 1 constant infusion (inf) protocol. Methylphenidate (MePhen) and
tetrabenazine (TBZ) were co-infused with radiotracer and haloperidol and apomorphine administered 30 min prior. Tissue/cortex ratios determined following the
infusion protocol represent equilibrium distribution volume ratios (DVR). Data are shown as mean 6 SD.
1Studies performed using dual radiotracer infusions.
*P , 0.005 vs control d-threo-[3H]MePhen infusion study.
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The calculation of distribution volume ratios from
the infusion studies requires reaching an equilibrium
of tissue radioactivity concentrations and selection of
an appropriate brain region for use as an estimate of
nonspecific binding. We had previously demonstrated
that a-(1)-[3H]DTBZ reached equilibrium by 60 min of
infusion (Kilbourn and Sherman, 1997). In this study
the equilibrium for d-threo-[3H]MePhen was also
clearly reached within this time frame, as the values
for striatum/cortex (and striatum/cerebellum, data not
shown) at 30 min were indistinguishable from those
obtained at 60 min. For both (1)-a-[11C]DTBZ and
d-threo-[3H]MePhen we have evaluated using either
the cerebellum or the cortex and the region of nonspe-
cific binding. For both radioligands there is minimal
specific binding in either region and as the cortex is the
brain region we and others have utilized for in vivo
imaging studies of these radioligands in human brain
(Frey et al., 1996; Lee et al., 2000), it was chosen in this
study. Using the same reference region for both radio-
tracers minimizes the experimental errors introduced
in tissue dissection and counting from a dual-radio-
tracer infusion protocol. (1)-a-[11C]DTBZ shows higher
specific binding in the striatum as compared to [3H]Me-
Phen, but both radiotracers have binding potentials
(BP 5 DVR 2 1) in the striatum which are within the
range suggested as suitable for measurements of
changes of in vivo radioligand binding due to physio-
logical or pharmacological challenges (Endres and Car-
son, 1998).
The use of a bolus injection of radiotracer, followed
by determination of regional brain concentrations of
radioactivity at a single time point, certainly offers a
simpler experimental protocol for estimating specific
binding. Most often, ratios between brain regions are
calculated at 1) the point of greatest difference between
the region of interest and a region purportedly void of
specific binding sites, or 2) at a time point occurring
within a time span when the ratios between tissues are
fairly steady. The estimated specific binding for (1)-a-
[11C]DTBZ and d-threo-[3H]MePhen determined here
following bolus injection can be compared to the equiv-
alent values determined by infusion studies (Tables I,
II). The choice of a time point for tissue analysis is
crucial. For d-threo-[3H]MePhen the distribution vol-
ume ratio estimated at 30 min after the bolus injection
is similar to that determined using the equilibrium
infusion method, but the choice of time for measure-
ment remains critical as the striatum/cerebellum ratio
clearly changes with time after a bolus administration
(Gatley et al., 1995; Kilbourn and Sherman, unpub-
lished data). For (1)-a-[11C]DTBZ, however, the spe-
cific binding estimate following the bolus injection was
higher than determined using the equilibrium ap-
proach and the difference is consistently seen with
sacrifice times chosen at both the peak striatal uptake
(15 min, DVR 5 3.76 6 0.15; Kilbourn and Sherman,
1997) and a later time point (30 min, this study). Thus,
the use of the bolus injection with a single time point
measurement of concentrations should be made with
caution and with an understanding of these possible
limitations.
Pharmacological specificity
Using the dual infusion of d-threo-[3H]MePhen and
(1)-a-[11C]DTBZ, the effects of three types of dopami-
nergic drugs were examined. Co-injection of tetraben-
azine, the specific and high-affinity inhibitor of the
VMAT2, completely eliminated specific binding of (1)-
a-[11C]DTBZ in the striatum and hypothalamus, but
did not affect the in vivo binding of d-threo-[3H]Me-
Phen. Conversely, coadministration of methylpheni-
date essentially completely reduced the specific bind-
ing of d-threo-[3H]MePhen, but had no effect on (1)-a-
[11C]DTBZ binding. These results were expected, as
each of these two drugs have been shown to be specific
for one type of transporter.
Administration of the dopamine receptor antagonist
(haloperidol) or agonist (apomorphine) had no signifi-
cant effect on either (1)-a-[11C]DTBZ or d-threo-
[3H]MePhen specific binding in any region of the rat
brain. These studies with a dopaminergic receptor li-
gand also demonstrate the lack of effect of changes in
blood flow on the equilibrium radiotracer measures,
since such drugs are known to significantly alter re-
gional cerebral blood flow rates in the rat brain (Ingvar
et al., 1983; McCulloch and Teasdale, 1979).
The lack of effect of methylphenidate or dopamine
receptor ligands on the in vivo binding of (1)-a-
[11C]DTBZ agrees with prior studies which have failed
to demonstrate regulation of the VMAT2 binding site
in the dopaminergic neurons of the rat striatum (by
such drugs as dopamine receptor ligands, dopamine
reuptake inhibitors, L-DOPA, or monoamine oxidase A
inhibitors) (Wilson and Kish, 1996; Naudon et al.,
1994; Vander Borght et al., 1995). Our results do not
match those of Fleckenstein and co-workers, who re-
cently reported a modest (20%) cocaine-induced in-
crease in binding of [3H]DTBZ in purified rat brain
synaptic vesicles (Brown et al., 2000), an effect also
observed for dopamine transporter inhibitors such as
amfonelic acid and GBR 12935. Methylphenidate, used
in this experiment, is an effective inhibitor of the DAT
and produces rapid changes in dopamine levels in the
rat brain (Gatley et al., 1999), but in our experiments it
did not alter in vivo radioligand binding to the VMAT2.
The explanation for these divergent results may be due
simply to different drug effects (methylphenidate vs.
cocaine) or the difference between in vitro studies
(Brown et al., 2000) and our in vivo studies; even for in
vitro assays, divergent results using radioligand bind-
ing of [3H]DTBZ have been reported, depending on the
tissue preparation (Hogan et al., 2000).
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Since TBZ rapidly and effectively depletes brain tis-
sues of dopamine (Kuszenski, 1977), as evidenced by
increased in vivo [11C]RAC binding (Dewey et al.,
1993), the lack of effect of TBZ on d-threo-[3H]MePhen
binding would support the prior conclusions (Gatley et
al., 1995) that this radioligand is not sensitive in vivo
to acute changes of endogenous levels of dopamine. The
lack of acute effects of dopaminergic drugs (other than
methylphenidate itself) on in vivo binding of this ra-
dioligand also suggests that occupation of dopamine
receptors does not induce rapid (,1 h) changes in the
binding of radioligands to the transporter; such lack of
effects of dopamine receptor agonists and antagonists
have been reported with other DAT radioligands such
as [11C]CFT and [125I]RTI-55 (Cline et al., 1992; Schef-
fel et al., 1996). However, it has been recently reported
that stimulants such as amphetamine, and more im-
portantly dopamine itself, induce a rapid internaliza-
tion of transporter protein in hDAT-expressing cell
lines (Saunders et al., 2000), resulting in a rapid loss of
DA uptake. As haloperidol and tetrabenazine should
have had significant effects on dopamine release and
turnover, the in vivo and in vitro data may not be in
agreement. It is not known if the radioligand em-
ployed in our in vivo studies, d-threo-[3H]MePhen, is
capable of binding to transporters which have been
trafficked to cytosolic sites; in that case, the in vivo
measures would simply be insensitive to the differ-
ential location of DAT at cell surface vs. internal
sites. Further studies in this area are needed to
understand the potential for in vivo radioligands to
measure the proportions of transporters in different
physical environments.
Finally, these studies provide some insight into the
importance of specific activity for in vivo radiotracer
studies and the potential for application of this tech-
nique to studies utilizing small animal PET imaging
devices. Most of the equilibrium infusion studies per-
formed here utilized 4 – 6 mCi of total carbon-11-
labeled radiotracer. For methylphenidate, using a
specific activity of approximately 500 Ci/mmol at
time of beginning the infusion and a molecular
weight of 233 g/mol, this calculates to a total injected
mass of nearly 2 mg for a 4 mCi infusion. Infusion
studies with the tritiated radioligand employed a
total of 10 mCi per animal; at a specific activity of 83
Ci/mmol, that is an injected dose of 0.027 mg. Despite
a mass dose difference of 75, the carbon-11 and tri-
tium-labeled radioligands provided equivalent in
vivo regional brain distributions and estimates of
specific binding. This provides encouragement that
sufficient amounts of carbon-11-labeled tracers
should be tolerated in future in vivo imaging studies
in rats and the use of the equilibrium infusions pro-
vide an excellent approach to quantification of spe-
cific binding.
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